Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,^* the implant demonstrated: 

Read more at globenewswire.com